Domain | Corporate Tax | DT
The Position
For allowability of busin...
By J the App
Pochiraju Industries had claimed ₹10.70 crore of expenditure relating to its Bio-Pharma division. ITAT found contemporaneous evidence in the company's Annual Report that the first phase of the unit had been fully implemented and production had started, and held that subsequent SARFAESI proceedings could not retrospectively change that position.
Domain | Corporate Tax | DT
The Position
For allowability of busin...
Read the full article in the app
This is a premium article. Download J the App to read the complete content.